KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Core Insights - Merck announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, evaluating KEYTRUDA® in combination with chemotherapy for platinum-resistant recurrent ovarian cancer [1] Group 1 - The trial, also known as ENGOT-ov65, assesses the efficacy of KEYTRUDA® (pembrolizumab) combined with paclitaxel, with or without bevacizumab [1]